molecular signatures. Indeed, applying immunohistochemistry for GATA3 on an independent series of cases, Wang et al also showed that GATA3 expression, evidenced in almost half of the cases, identifies a high-risk subset of PTCL, NOS. Although the findings in these 2 independent cohorts are convergent, it will be useful to confirm the clinical correlation of the GATA3 vs TBX21 profiles in another series of PTCL, NOS patients, if possible in the setting of a trial where homogeneous therapy is applied.
Having shown that molecular signatures in PTCL, NOS have a clinical impact, an important question is whether there is a rationale to suggest that these molecular subgroups may benefit from distinct, innovative, and potentially more efficient therapies. Investigating whether the molecular subgroups differ in terms of pathogenesis and oncogenic pathways is a prerequisite to identify novel druggable targets. Evidence for enrichment in intracellular pathways such as the phosphoinositide 3-kinase-associated gene signature in the GATA3 subgroup provides a basis for intervention with specific inhibitors. The experimental data provided in the study by Wang et al point at the role of the tumor microenvironment and how Th2 cytokines may contribute to shaping the phenotype of both the lymphoma cells and tumor-associated macrophages, functionally polarized to promote neoplastic growth, suggesting that tumor microenvironment may represent a therapeutic target. Finally, novel recurrent mutations expected to be discovered by the ongoing high-throughput and deep sequencing studies may segregate with molecular subgroups and possibly provide insights into novel therapies. Bortezomib resistance and MUC1 in myeloma
In this issue of Blood, Yin et al make the novel discovery that targeting the mucin 1 C-terminal subunit (MUC1-C) oncoprotein reverses resistance to the proteasome inhibitor bortezomib in multiple myeloma cells by triggering depletion of glutathione (GSH) pools and induction of oxidative injury. They also report that these events proceed through a process involving downregulation of the p53-inducible regulator of glycolysis and apoptosis (TIGAR). Specifically, the authors show that MM cells resistant to bortezomib display compensatory upregulation of TIGAR and GSH and that these responses are blocked by a pharmacologic inhibitor of MUC1-C (GO-203), resulting in a marked synergistic increase in reactive oxygen species (ROS) and cell death. One of the more interesting features of this study is that it touches on multiple concepts, including drug resistance, oncogene addiction, oncogenic stress, and inhibition of stress-related pathways in a manner that has very clear translational implications. The question naturally arose whether, and by what mechanism, disabling this defensive oxidative stress system might modify the response of bortezomib-resistant myeloma cells to bortezomib. Despite the impressive activity of proteasome inhibitors such as bortezomib and carfilzomib in myeloma, their primary mode of action remains uncertain and has been variably ascribed to NF-kB inactivation, induction of proteotoxic stress, and accumulation of proapoptotic proteins, among numerous others. Analogously, the basis for bortezomib resistance is unclear, and although preclinical studies have implicated multidrug resistance efflux mechanisms or proteasome subunit mutations, the relevance of these factors for resistance in patients remains to be established. 4 Interestingly, a link between proteasome inhibitor actions and induction of ROS/oxidative injury in neoplastic cells has long been recognized. 9 Consistent with this observation, it is noteworthy that Lin et al found that bortezomib-resistant myeloma cells exhibited amplified activation of antioxidant defenses through the MUC1-TIGAR-GSH axis in response to bortezomib and that blocking this response, for example, by GO-203, significantly increased oxidative injury (eg, superoxide and hydrogen peroxide generation) and cell death. A model summarizing these points is illustrated in the figure. Notably, in bortezomib-sensitive cells, oxidative injury also stimulated lethal components of the unfolded-protein response (UPR), for example, CCAAT/enhancer binding protein homologous protein (CHOP) upregulation, potentially contributing to cell death. The UPR represents a cellular response to the accumulation of mal-folded proteins in the endoplasmic reticulum (endoplasmic reticulum stress), and although it initially plays a cytoprotective role, if unresolved it can transform into a proapoptotic one. Together, these findings are consistent with a model in which MUC1 and its downstream effectors protect myeloma cells from both intrinsic and bortezomib-induced oxidative and proteotoxic stress, and that interference with this defensive mechanism renders myeloma cells particularly sensitive to noxious stimuli. Such a model is consistent with the strategy of targeting socalled "orthogonal" pathways, that is, those that are not directly responsible for neoplastic transformation, such as those related to oncoproteins with driver mutations, but instead are required to protect neoplastic cells from resulting oncogenic stresses. 10 These findings raise multiple questions that could stimulate a variety of future investigations and identification of therapeutic opportunities. For, example, it will be interesting to determine whether the capacity of agents like GO-203 to disrupt the MUC1 pathway and overcome bortezomib resistance is restricted to bortezomib or could be extended to newer-generation proteasome inhibitors such as carfilzomib, which demonstrates intrinsic activity in some bortezomib-resistant cells. In this context, it will also be interesting to determine whether these findings could also be extended to other inhibitors of the ubiquitin-proteasome system, for example, neural precursor cell expressed, developmentally downregulated 8 or deubiquitinase inhibitors, which may also trigger oxidative or proteotoxic stress. Significantly, some of these agents have now entered the clinical arena. A question also arises of whether this strategy might be effective in other hematologic malignancies in which proteasome inhibitors have established (eg, mantle cell lymphoma) or potential (eg, activated B-cell-diffuse large B-cell lymphoma) therapeutic roles. In particular, extension of these findings to solid tumors, which for unknown reasons remain largely unresponsive to proteasome inhibitors, would obviously have major implications. Additionally, it will be critical to determine whether similar resistance mechanisms are operative in cells obtained from patients exposed to proteasome inhibitors in vivo, and if so, whether circumvention of resistance ensues. Finally, it will be important to identify the mechanism(s) by which this strategy selectively enhances proteasome inhibitor lethality in neoplastic compared with normal cells, thereby increasing the therapeutic index. Given ongoing efforts to develop GO-203 for clinical use, answers to several of these questions, and potentially validation of this strategy, are likely to be addressed in the not too distant future.
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